HELP Latest Headlines

Helus Pharma’s Phase 3 Enrollment Hits 86%: What Sets Its Breakthrough Depression Drug Apart Ahead of Crucial Q4 2026 Data?

Market Chameleon (Fri, 26-Jun 9:43 AM)

Helus Pharma Targets Major Depression With $50 Million Underwritten Offering—Funding Phase 3 HLP003 Data and Expansion

Market Chameleon (Thu, 25-Jun 10:35 AM)

Helus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug Pipeline

at www.tipranks.com (Thu, 25-Jun 11:28 AM)

Jefferies Sticks to Their Buy Rating for Helus Pharma (HELP)

at www.tipranks.com (Thu, 25-Jun 9:06 AM)

Helus Pharma Prices US$50 Million Equity Offering to Advance Mental Health Drug Pipeline

at www.tipranks.com (Thu, 25-Jun 6:32 AM)

Helus Pharma Raises $50 Million for Phase 3 Depression Drug as Underwritten Offering Priced at $4.85 per Share

Market Chameleon (Wed, 24-Jun 11:09 AM)

Helus Pharma’s $50 Million Offering Aims to Accelerate Key Mental Health Drug Trials

Market Chameleon (Wed, 24-Jun 7:06 AM)

Helus Pharma prices $50M public offering at $4.85 per share

at seekingalpha.com (Wed, 24-Jun 6:34 AM)

Helus Pharma Highlights Progress in Mental Health Innovation with Milken Institute Conference Appearance

Market Chameleon (Thu, 30-Apr 8:02 AM)

Helus Pharma and TARA Mind Target Veteran Mental Health—Phase 3 Recruitment for HLP003 Ramps Up

Market Chameleon (Tue, 28-Apr 7:59 AM)

Helus Pharma Bolsters Scientific Board with Leading Figures as Pipeline Advances Toward Key Milestones

Market Chameleon (Thu, 23-Apr 7:39 AM)

Helus Pharma’s CEO Transition Highlights Strategic Focus on Mental Health Pipeline

Market Chameleon (Mon, 20-Apr 9:54 AM)

Helus Pharma CEO Transition Highlights Strategic Focus on Mental Health Pipeline and Upcoming Clinical Milestones

Market Chameleon (Mon, 20-Apr 8:13 AM)